J&J rounds out the year with twin buyouts, gaining control of delivery and surgical robotics tech

J&J is scooping up one of Bristol-Myers-Squibb’s biotech partners specialized in bladder biology, with a particularly keen interest in a technology that releases cancer drugs locally. The pharma giant isn’t looking to make a splash here — the financial terms remain undisclosed — but they are clear that they see

Read the full article here

Related Articles